Jones Financial Companies Lllp reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 45,406 shares of the medical research company’s stock after selling 191 shares during the period. Jones Financial Companies Lllp’s holdings in Thermo Fisher Scientific were worth $13,335,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently added to or reduced their stakes in the company. FMR LLC raised its holdings in Thermo Fisher Scientific by 33.5% in the 1st quarter. FMR LLC now owns 11,572,581 shares of the medical research company’s stock worth $3,167,647,000 after purchasing an additional 2,900,868 shares during the period. BlackRock Inc. raised its holdings in Thermo Fisher Scientific by 4.1% in the 1st quarter. BlackRock Inc. now owns 27,251,678 shares of the medical research company’s stock worth $7,459,327,000 after purchasing an additional 1,074,400 shares during the period. Marshall Wace LLP raised its holdings in Thermo Fisher Scientific by 361.8% in the 1st quarter. Marshall Wace LLP now owns 775,103 shares of the medical research company’s stock worth $212,161,000 after purchasing an additional 607,245 shares during the period. Janus Henderson Group PLC raised its holdings in Thermo Fisher Scientific by 22.9% in the 2nd quarter. Janus Henderson Group PLC now owns 2,986,916 shares of the medical research company’s stock worth $877,186,000 after purchasing an additional 555,802 shares during the period. Finally, Swedbank bought a new position in Thermo Fisher Scientific in the 1st quarter worth $111,710,000. Hedge funds and other institutional investors own 88.21% of the company’s stock.
In other news, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $268.29, for a total value of $670,725.00. Following the sale, the chief financial officer now directly owns 40,029 shares of the company’s stock, valued at $10,739,380.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director C Martin Harris sold 275 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $270.73, for a total value of $74,450.75. Following the completion of the sale, the director now directly owns 6,433 shares in the company, valued at $1,741,606.09. The disclosure for this sale can be found here. Insiders sold 52,775 shares of company stock worth $14,986,676 over the last ninety days. Insiders own 0.45% of the company’s stock.
NYSE:TMO traded up $2.84 on Friday, reaching $276.15. 992,900 shares of the company’s stock traded hands, compared to its average volume of 1,599,691. The company has a quick ratio of 1.07, a current ratio of 1.49 and a debt-to-equity ratio of 0.58. The stock has a 50-day simple moving average of $286.98 and a 200-day simple moving average of $272.14. The firm has a market cap of $107.92 billion, a PE ratio of 22.99, a P/E/G ratio of 1.76 and a beta of 1.11. Thermo Fisher Scientific Inc. has a 12 month low of $208.34 and a 12 month high of $305.45.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.04 EPS for the quarter, beating the Zacks’ consensus estimate of $3.01 by $0.03. The business had revenue of $6.32 billion for the quarter, compared to analysts’ expectations of $6.31 billion. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. The business’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period last year, the firm earned $2.75 earnings per share. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 12.24 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Tuesday, September 17th will be issued a dividend of $0.19 per share. The ex-dividend date is Monday, September 16th. This represents a $0.76 dividend on an annualized basis and a yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio is presently 6.83%.
TMO has been the topic of a number of recent research reports. Needham & Company LLC raised their target price on Thermo Fisher Scientific from $315.00 to $321.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 target price on the stock in a report on Wednesday, June 12th. Wolfe Research began coverage on Thermo Fisher Scientific in a report on Thursday, May 30th. They set an “outperform” rating on the stock. Credit Suisse Group reissued a “buy” rating and set a $310.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, July 31st. Finally, Barclays set a $330.00 price target on Thermo Fisher Scientific and gave the company a “buy” rating in a report on Monday, July 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $303.17.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Further Reading: What Factors Can Affect Return on Equity?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.